Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer.

× No keyword cloud information.

21 in total

Review 1. Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?

Authors: Martin J Cannon; Hannah Goyne; Pamela J B Stone; Maurizio Chiriva-Internati
Journal: Expert Opin Biol Ther Date: 2011-01-28 Impact factor: 4.388

2. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells.

Authors: Li Wang; Karina Pino-Lagos; Victor C de Vries; Indira Guleria; Mohamed H Sayegh; Randolph J Noelle
Journal: Proc Natl Acad Sci U S A Date: 2008-07-02 Impact factor: 11.205

3. Th17 cells in ovarian cancer.

Authors: David H Munn
Journal: Blood Date: 2009-08-06 Impact factor: 22.113

4. Cyclophosphamide induces differentiation of Th17 cells in cancer patients.

Authors: Sophie Viaud; Caroline Flament; Mustapha Zoubir; Patricia Pautier; Axel LeCesne; Vincent Ribrag; Jean-Charles Soria; Virginie Marty; Philippe Vielh; Caroline Robert; Nathalie Chaput; Laurence Zitvogel
Journal: Cancer Res Date: 2010-12-09 Impact factor: 12.701

5. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.

Authors: Ilona Kryczek; Shuang Wei; Gefeng Zhu; Leann Myers; Peter Mottram; Pui Cheng; Lieping Chen; George Coukos; Weiping Zou
Journal: Cancer Res Date: 2007-09-15 Impact factor: 12.701

6. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors: Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal: Nat Med Date: 2004-08-22 Impact factor: 53.440

7. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.

Authors: Panagiotis Tsagozis; Fredrik Eriksson; Pavel Pisa
Journal: Cancer Immunol Immunother Date: 2008-02-23 Impact factor: 6.968

8. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Authors: Ilona Kryczek; Mousumi Banerjee; Pui Cheng; Linhua Vatan; Wojciech Szeliga; Shuang Wei; Emina Huang; Emily Finlayson; Diane Simeone; Theodore H Welling; Alfred Chang; George Coukos; Rebecca Liu; Weiping Zou
Journal: Blood Date: 2009-05-21 Impact factor: 22.113

9. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors: R J North
Journal: J Exp Med Date: 1982-04-01 Impact factor: 14.307

10. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

Authors: Marta Coscia; Elena Quaglino; Manuela Iezzi; Claudia Curcio; Francesca Pantaleoni; Chiara Riganti; Ingunn Holen; Hannu Mönkkönen; Mario Boccadoro; Guido Forni; Piero Musiani; Amalia Bosia; Federica Cavallo; Massimo Massaia
Journal: J Cell Mol Med Date: 2010-12 Impact factor: 5.310

2 in total

1. Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy.

Authors: R Kleef; S Kekic; N Ludwig
Journal: Case Rep Oncol Date: 2012-05-05

Review 2. Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer.

Authors: Hannah E Goyne; Martin J Cannon
Journal: Front Immunol Date: 2013-11-18 Impact factor: 7.561

2 in total